Objective-Innate lymphoid cells (ILCs) are a newly discovered subset of immune cells that promote tissue homeostasis and protect against pathogens. ILCs produce cytokines also produced by T lymphocytes that have been shown to affect atherosclerosis, but the influence of ILCs on atherosclerosis has not been explored. mice were concurrently fed an atherogenic diet and treated with either ILC-depleting anti-CD90.2 antibodies or IL-2/ anti-IL-2 complexes that expand CD25 + ILCs. Lesion development was not affected by anti-CD90.2 treatment, but was reduced in IL-2/anti-IL-2-treated mice. These IL-2-treated mice had reduced very low-density lipoprotein cholesterol and increased triglycerides compared with controls and reduced apolipoprotein B100 gene expression in the liver. IL-2/ anti-IL-2 treatment caused expansion of ILC2s in aorta and other tissues, elevated levels of IL-5, systemic eosinophila, and hepatic eosinophilic inflammation. Blockade of IL-5 reversed the IL-2 complex-induced eosinophilia but did not change lesion size. 
T he development of atherosclerotic lesions and the destabilization of established lesions are promoted by local arterial and systemic inflammation driven by innate and adaptive immune responses. Interferon-γ IFN-γ-secreting T H 1 cells enhance lesion development, but the influence of T H 2 or T H 17 cells is uncertain. 1 Innate lymphoid cells (ILCs) have emerged as important effector cells in both protective immunity against pathogens and immune/inflammatory diseases. 2, 3 Each subset of ILCs, types 1, 2, or 3, secretes a distinct group of cytokines. The pattern of cytokine production corresponds approximately to that of its T-cell counterpart: ILC1s secrete Th1-related cytokines, ILC2s secrete Th2-related cytokines, and ILC3s secrete Th17-related cytokines. The influence of each of these ILC subsets to atherosclerosis is largely unknown. Natural killer cells, which are cytotoxic and IFN-γ-secreting innate cells that are phenotypically related to the ILC1 subset, seem to promote atherosclerotic lesion development in mice. 4 The contribution of noncytotoxic IFN-γ-secreting ILC1s has not been addressed. Group 2 ILCs secrete IL-4, IL-5, IL-9, and IL-13 in response to IL-25, IL-33, and TSLP (thymic stromal lymphopoietin). These cells play a role in metabolic homeostasis by reducing adiposity, a function mediated in part by IL-5-dependent eosinophil activation. [5] [6] [7] As of yet, there is no ILC-specific knockout mouse line that does not also have deficiencies in other lymphocyte populations. 8 However, injections of anti-CD90 antibodies selectively deplete CD90-expressing ILCs in V-D-J recombinase-1 or recombinase-2 (rag1 or rag2)-deficient mice that lack all lymphocytes, and this strategy has been used to assess the role of ILCs in health and disease. 9, 10 It was recently shown that administration of IL-2 complexed with a particular anti-IL-2 antibody (clone JES6-1) to rag1 −/− mice selectively allows expansion of CD25 + ILC2s.
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In immunocompetent mice, treatment of mice with IL-2/anti-IL-2 complexes expands regulatory T cells, 12, 13 and it has been proposed as a therapeutic approach for autoimmunity, graft versus host disease, and allograft rejection.
14 IL-2/anti-IL-2 complex therapy reduces atherosclerotic lesion development in mice, 15, 16 but the effect of this therapy on ILC expansion in atherosclerosis models in not known.
In this study, we investigated the influence of ILCs on atherosclerotic lesion development. We used antibody-mediated global ILC depletion and IL-2/anti-IL-2-driven expansion in ldlr −/− rag1 −/− mice, which are atherosclerosis prone but lack adaptive immune cells. We show that IL-5-producing ILCs are present in atherosclerotic aortas. Global depletion of all CD90 + ILCs, which include the majority of all 3 groups of ILCs, leads to a reduction in types 1, 2, and 3 cytokine production in the spleen, with no net effect on atherosclerotic lesion development. However, IL-2/anti-IL-2 treatment results in a marked increase in ILC2s, eosinophilia, reduced very lowdensity lipoprotein (VLDL) cholesterol levels and protection against atherosclerotic lesion development. The results highlight the potential role of therapeutic expansion of type 2 ILCs for the treatment of atherosclerotic vascular disease.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. 
Results

Aortic
Depletion and Expansion of ILCs in Hypercholesterolemic Mice
To evaluate the role of ILCs in atherosclerosis, we adopted 2 approaches previously used to study ILC depletion or expansion in the context of mouse models of immune defense and inflammatory diseases. 
IL-2/Anti-IL-2 Complex Treatment Reduces Atherosclerosis
Aortic roots from mice fed HFD for 7 weeks were sectioned and aortic sinus lesions were analyzed. Strikingly, mice treated with IL-2/JES6-1 had significantly reduced lesion size (85 608±12 744 μm 
IL-2/Anti-IL-2 Complex Treatment Reduces Serum VLDL Levels and It Is Associated With Reduced Hepatic Apolipoprotein B Expression
We did not observe weight changes ( Figure 4C ) as a consequence of either ILC depletion or expansion. However, injection of IL-2/JES6-1 caused a change in lipid profile. Levels of total cholesterol ( Figure 4D ) were decreased, whereas triglycerides ( Figure 4E ) were increased in IL-2/JES6-1-treated mice. High-performance liquid chromatography analysis revealed that the reduction in cholesterol was located in the chylomicron and VLDL fraction, whereas LDL and high-density lipoprotein levels were similar between groups ( Figure 4F ). The increased levels of triglycerides were mainly located in the VLDL compartment ( Figure 4G ). To test, if expansion of CD25 + ILCs affected lipoprotein production, we measured genes associated with lipid metabolism. Transcription of apolipoprotein B (apob) was markedly reduced in the livers from IL-2/JES6-1-treated mice ( Figure 4H ), whereas hepatic lipase (lipc), apolipoprotein C-III (apoc3), and the triglyceride-synthesizing enzyme diglyceride acetyltransferase (dgat) were expressed at similar levels between groups (Figure VIA-VIC in the online-only Data Supplement).
Previous studies have demonstrated that type 2 ILCs may promote hepatic fibrosis. 17 To address this, we fed mice HFD To assess liver function, we measured soluble markers of liver damage in serum. Levels of aspartate aminotransferase were similar between groups but alanine aminotransferase was increased by IL-2 complex treatment ( Figure Figure 5A ) and increased levels of eosinophils in blood ( Figure 5B ).
We further investigated whether IL-2/anti-IL-2 complex treatment led to accumulation of eosinophils in tissues. Leukocyte fractions from tissues were isolated and analyzed by flow cytometry. Eosinophil accumulation to visceral adipose tissue and liver ( Figure 5C ) was dramatically enhanced by IL-2/anti-IL-2 treatment. Furthermore, eosinophil accumulation in the aorta was increased by 75-fold IL-2/JES6-1 treatment ( Figure 5C ) and 99% of the eosinophils were located in PVAT (182±59 eosinophils in aorta without PVAT and 19064±11400 eosinophils in aorta with PVAT).
IL-5 Blockade Inhibits IL-2 Complex-Induced Eosinophilia But Not Affect Atherosclerosis
We hypothesized that the high levels of IL-5 induced after IL-2 complex injections affected atherosclerosis. To investigate this, mice (ldlr−/−rag1−/−) were fed HFD for 7 weeks and treated for the past 4 weeks with IL-2 complexes supplemented with anti-IL-5 (clone: TRFK5) or an isotype control (n=7/group). Anti-IL-5 efficiently blocked eosinophilia in IL-2/anti-IL-2-treated mice (>90% reduction; Figure 6A ) as well blocked eosinophil accumulation in the atherosclerotic aorta (>90% reduction; Figure 6B ). Moreover, accumulation of eosinophils was found to be reduced in the liver or the epididymal adipose tissue ( Figure VIIIA and VIIIB in the onlineonly Data Supplement). Anti-IL-5 treatment did not affect levels of aortic ILC2s ( Figure 6C ). Aortic sinus lesions were comparable between mice treated with IL-2/anti-IL-2 complexes plus either control IgG (141 594±25 343 μm 2 ) or anti-IL-5 (100 582±25 470 μm 2 ; Figure 6D , P=0.2) and cholesterol levels were similar ( Figure 6E ). The serum levels of triglycerides were higher in the anti-L5-treated group, but the difference did not reach statistical significance ( Figure 6F 
Discussion
ILCs have been shown to play important roles in inflammatory diseases and in maintaining barrier homeostasis. Previous work has demonstrated that several cytokines influence atherosclerotic disease in different ways. 1 Many of these cytokines, previously considered to be T H cell derived have recently been shown to be produced by ILCs. Our study demonstrates that ILCs, in particular CD25 + ILC2s, can influence atherosclerosis. A few recent studies have indirectly suggested a role for ILCs in atherosclerosis. The ILC2-activating cytokines IL-25 19 and IL-33 20 have been shown to reduce atherosclerosis. Also, the transcription factor Id3 was shown to regulate IL-5 production of lin
+ ILCs present in the aorta of atherosclerotic mice. 21 However, this is the first study to directly examine the effects of ILC expansion or depletion on atherosclerosis.
We demonstrate that IL-5-producing CD25 + ILCs are present in atherosclerotic mouse aortas. These cells are expanded . D, Lesion area in the aortic root and levels of (E) triglycerides and (F) cholesterol. G, Serum levels of alanine aminotransferase. H, Hematoxylin and eosin staining of liver sections (×40 magnification). n=7/group. **P<0.01, ***P<0.001.
by treatment of mice with IL-2/anti-IL-2 complexes, inhibiting atherosclerotic lesion formation. IL-5 has been shown to be atheroprotective by promoting the secretion of natural antibodies by B-1 cells. 22 As ldlr −/− rag1 −/− mice lack B-1 cells, our model allows us to study the B-1 cell-independent effects of IL-5. One such effect is the role for IL-5 in inducing mobilization and proliferation of eosinophils. We found that IL-2/ JES6-1 treatment generated a marked increase in circulating and tissue eosinophils. However, blockade of IL-5 in mice given IL-2 complexes did not significantly affect atherosclerosis. This intriguing finding suggests that CD25 + ILCs may act in an IL-5-independent manner to limit atherosclerotic burden.
The atheroprotective potential of ILC2s in our study probably relates, in part, to alterations in lipid metabolism. Expansion of CD25-expressing ILCs resulted in reduced VLDL cholesterol levels. This atheroprotective phenotype was associated with reduced expression of the Apob gene in the liver. However, mRNA levels of Lipc, Dgat2, or Apoc3 were not affected by IL-2/JES6-1 treatment, showing that other aspects of liver function were intact. As IL-5 blockade did not affect cholesterol levels, the cholesterol-lowering effect of IL-2 complexes may possibly be mediated by IL-13, other ILC2-related soluble mediators or by cell-cell dependent mechanisms. Arguing against a potential role of IL-13 in this study is the fact that IL-2 complex treatment did not increase levels of IL-13 in serum, although it is difficult to estimate how well local production of IL-13 in the tissue is reflected in the circulation. Also, we cannot completely exclude the role of other CD25-expressing cells in affecting cholesterol. Surprisingly, the IL-2/JES6-1-treated mice exhibited elevated triglyceride levels. Others have shown that deficiency in IL-5 production results in increased adiposity. 23 Conversely, we observed a decrease in epididymal visceral adipose tissue in mice treated with IL-2/anti-IL-2 complexes, which have high levels of circulating IL-5. Because anti-IL-5 appeared no to fully block the rise in triglycerides in HFD-fed ldlr −/− rag1 −/− treated with IL-2/anti-IL-2 complexes, thus the elevated numbers of eosinophils may not be responsible for the IL-2/ anti-IL-2 effect on serum triglycerides. Possibly, ILC2 activation compromises storage of triglyceride in adipose tissue, leading to high levels of triglycerides in the serum, through an IL-5-independent mechanism. Altogether our data suggests that ILC2s may affect atherosclerosis primarily by influencing metabolism rather than acting directly in the lesion. However, further investigation is required to determine if there are direct atheroprotective effects of ILC2s within lesions, such as by influencing macrophage phenotype. We found that HFD did not influence numbers of ILCs in the aorta or percent ILCs in the spleen. However, the proportion of CD25 + ILCs to total leukocytes was reduced in the atherosclerotic artery, indicating that relative levels of anti-atherogenic CD25 + ILCs drop as atherosclerosis progresses.
The role of eosinophils in atherosclerosis has not yet been addressed in experimental models. Human carotid plaques were found to have expression of eotaxin and CCR3 but no significant levels of eosinophils were detected. 18 We found that most eosinophils were localized to the PVAT and not to actual lesion, indicating that eosinophils do not influence lesion development through actions within the plaque. Further studies using eosinophil-deficient mice models are needed to further understand the role of eosinophils in atherosclerosis development.
Treatment with IL-2/JES6-1 immune complexes has been shown to reduce atherosclerosis in ldlr −/− mice, which has been attributed to the expansion of regulatory T cells. 15, 16 The ldlr −/− rag1 −/− mouse lacks regulatory T cells, and the only known CD25 + cells that will respond to IL-2/JES6-1 are ILCs. 11 Thus, our findings suggest that part of the effect of IL-2/JES6-1 treatment observed in these studies may be because of expansion of CD25-expressing ILCs. It should be noted that expansion of ILCs is probably more pronounced in ldlr −/− rag1 −/− than in immunocompetent mice because of reduced competition for available IL-2 complexes in the absence of regulatory T cells.
Given the atheroprotective effect of IL-2/JES6-1 treatment, it may be considered surprising that depletion of ILCs by anti-CD90.2 did not affect lesion size or composition. There are several possible explanations for this finding. First, depletion of ILCs by anti-CD90.2 injections removes several different classes of ILCs with potentially opposite effects on atherosclerosis. It is conceivable, given knowledge from cytokine knockout mice, 24, 25 that ILC1s, ILC3s, and CD90-expressing natural killer cells may promote atherosclerosis, whereas ILC2s may be atheroprotective. The role of these subsets needs to be addressed in future studies. Second, treatment of mice with CD90 effectively depleted all splenic cells capable of secreting these cytokines, but failed to remove all ILC2s from the aortic wall. This is consistent with previous reports of failure of anti-CD90.2 treatment to deplete dermal ILC2s. In summary, we demonstrate that expansion of CD25-expressing ILCs, including ILC2s, results in atheroprotection in ldlr −/− rag1 −/− mice. Our study highlights the potential of ILC modulation as a pharmacological target for the treatment of cardiovascular disease and demonstrates the interaction between innate type 2 immunity and metabolism.
